- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Epilepsy
- Meeting Date: November 2022
- Public Summary Document (PSD) November 2022 PBAC Meeting - (PDF 497KB)
- Public Summary Document (PSD) November 2022 PBAC Meeting - (Word 66KB)
Midazolam – November 2022
Midazolam: Oromucosal solution in pre-filled syringe 2.5 mg in 0.25 mL, Oromucosal solution in pre-filled syringe 5 mg in 0.5 mL, Oromucosal solution in pre-filled syringe 7.5 mg in 0.75 mL, Oromucosal solution in pre-filled syringe 10 mg in 1 mL; Zyamis®
Last updated
3 March 2023
